We previously showed that aberrant histone modifications present on differentiation pathway genes play a critical role in the lack of response and that epigenetic therapy with an inhibitor of LSD1 could reprogram AML cells to respond to ATRA (Glasow et al., 2008; Schenk et al., 2012). This evidence concerns the gene KDM1A and acute myeloid leukemia.